Velpanat
Utilized to address chronic hepatitis c and indicated to support viral clearance.
- Category
- Antivirals
- Active ingredients
- Sofosbuvir · Velpatasvir
- Supply
- Pharmacy
- Route
- Oral use
- Form
- Tablet
- Strengths
- 400/100mg
Velpanat details
- Condition
- Chronic Hepatitis C
- Alternative names
- Epclusa
- Therapeutic class
- Antiviral
- Pharmacological class
- HCV NS5B inhibitor; HCV NS5A inhibitor
- Contraindications
- hypersensitivity to active substances
- Precautions and warnings
- monitor hepatic function
- Minor side effects
- headache; fatigue; nausea
- Moderate side effects
- insomnia; rash
- Serious side effects
- bradycardia, requires immediate medical attention
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Pharmacist only, dispensed without a prescription
- Manufacturer
- Natco Pharma
- Onset Time
- not applicable
- Duration
- 24 hours
- Storage instructions
- Store below 30°C.
- Drug interactions
- Amiodarone; Proton pump inhibitors; St. John's Wort
- Age restrictions
- For adult use.
Patient summary
Utilized to address chronic hepatitis c and indicated to support viral clearance.
Mechanism of action
Velpanat combines a nucleotide polymerase inhibitor (sofosbuvir) and a replication complex inhibitor (velpatasvir) to block hepatitis C virus replication, effectively targeting the viral life cycle.
Pregnancy and breastfeeding
Pregnancy: Not recommended unless necessary provided by specialist. Breastfeeding: Consult specialist.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Velpanat
Velpanat is a formulation of Sofosbuvir and Velpatasvir, used to treat the viral infection known as Chronic Hepatitis C. This combination is also marketed under the brand name Epclusa. The medicine is manufactured by Natco Pharma and supplied as a 400/100mg tablet intended for regular, consistent use over an extended period.
Velpanat availability in Asia
Velpanat is registered across 13 markets including the UAE, Singapore and Hong Kong, with availability also in Thailand, Malaysia and the Philippines. Generic Sofosbuvir and Velpatasvir, as much of it is produced in India, often provides a more affordable alternative to the original brand for patients living far from a major city or a well-stocked medical facility. This medicine is best used under a doctor’s care to monitor treatment progress, especially for expats seeking ongoing, reliable access across these regions.